Invivyd, Inc. (IVVD)
| Market Cap | 391.68M |
| Revenue (ttm) | 53.43M |
| Net Income (ttm) | -52.49M |
| Shares Out | 282.80M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,225,295 |
| Open | 1.460 |
| Previous Close | 1.460 |
| Day's Range | 1.370 - 1.500 |
| 52-Week Range | 0.483 - 3.070 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 8.75 (+531.77%) |
| Earnings Date | May 14, 2026 |
About IVVD
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatmen... [Read more]
Financial Performance
In 2025, Invivyd's revenue was $53.43 million, an increase of 110.47% compared to the previous year's $25.38 million. Losses were -$52.49 million, -69.11% less than in 2024.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IVVD stock is "Strong Buy." The 12-month stock price target is $8.75, which is an increase of 531.77% from the latest price.
News
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21 Event to be live streamed between 9:00 AM – 1:00 PM ET NEW H...
Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program
The company said its Phase 3 DECLARATION trial evaluating VYD2311 for COVID-19 prevention has reached a key interim milestone.
Invivyd Transcript: Study update
VYD2311, a next-gen COVID-19 monoclonal antibody, is advancing in a pivotal study with expanded enrollment and strong FDA collaboration, while a novel measles antibody, VMS-063, shows high preclinical potency and targets unmet needs amid rising outbreaks. Both programs aim to complement or surpass vaccines for vulnerable populations.
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
NEW HAVEN, Conn., April 09, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced progress in its REVOLUTION clinical program for VYD2311, a novel monoclonal antibody investigational c...
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW HAVEN, Conn., April 06, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on April 1, 2026, Invivyd granted 16 newly hired non-executive employees options to purchase an a...
Invivyd Announces Presentation at the World Vaccine Congress Washington
NEW HAVEN, Conn., March 30, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Robert Allen, Ph.D., Chief Scientific Officer at Invivyd, presented as part of the Antibodies for...
Invivyd Earnings Call Transcript: Q4 2025
REVOLUTION clinical program advanced with DECLARATION study reaching target enrollment and positive safety review. Q4 revenues grew 31% sequentially, and strong cash reserves support pivotal VYD2311 data in mid-2026. PEMGARDA adoption and pipeline expansion position the company for broader market impact.
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business hi...
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
NEW HAVEN, Conn., March 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Michael Mina, M.D., Ph.D., as Chief Medical Officer.
Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026
NEW HAVEN, Conn., March 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced ...
New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies
NEW HAVEN, Conn., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a peer-reviewed publication by Invivyd that uses data from the recent CANOPY pivotal clinical trial of ...
Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration
NEW HAVEN, Conn., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has received and is aligned with advice from the U.S. Food and Drug Administration (FDA) on the LIBE...
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody ...
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an inv...
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced initiation of the DECLARATION trial evaluating VYD2311, an investigational vaccine-alternative monoclon...
Invivyd Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing 2311, a next-generation intramuscular COVID prevention antibody, into pivotal trials, aiming for FDA submission by mid-2026 and broader patient access at a lower cost. The product offers higher potency, easier administration, and is positioned as a vaccine alternative.
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on...
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced it has identified and nominated for preclinical development a potentially best-in-class monoclonal anti...
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday.
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced the pricing of an underwritten public offering of 44,000,000 shares of its common stock at an...
Invivyd Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Invivyd) (Nasdaq: IVVD) today announced that it has commenced an underwritten public offering of shares of its common stock. In addit...
Invivyd Earnings Call Transcript: Q3 2025
Q3 2025 saw strong PEMGARDA revenue growth, a major capital raise, and pivotal progress for VYD2311, with key clinical studies set to launch and robust commercial expansion underway. The company is well-funded through mid-2026 pivotal data.
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
NEW HAVEN, Conn., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended September 30, 2025, and provided recent business highlights.
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced t...